Invitation Extended: New Chinese Policies Aim To Lure Foreign Pharma Firms
Improved Dialog Among Plans
Executive Summary
In their latest charm offensive, Chinese regulators issue policies clearly designed to encourage the import of innovative drugs from overseas and better serve foreign drug makers already operating in the country.
You may also be interested in...
Shionogi Files Antiviral NDA In China, Eyes Wider Use
Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.
New Chinese-Language Podcast: 聊聊生物制药热门话题
Join our China-based content team for this inaugural Chinese-language podcast discussing selected recent hot topics impacting the biopharma industry in China, including bispecific antibodies, antibody-drug conjugates and new regulatory policies designed to speed product approvals.
New Chinese-Language Podcast: 聊聊生物制药热门话题
Join our China-based content team for this inaugural Chinese-language podcast discussing selected recent hot topics impacting the biopharma industry in China, including bispecific antibodies, antibody-drug conjugates and new regulatory policies designed to speed product approvals.